In an interview with PharmaShots, Wildon R. Farwell, M.D., MPH, Global Medical Head of Neuromuscular Diseases at Biogen shared his views on the P-IV RESPOND study that assesses the benefits of Spinraza in patients treated with Zolgensma.Shots:RESPOND is a two-year, open-label study to evaluate the efficacy and safety of Spinraza (nusinersen) in infants and children with spinal muscular…
